Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.73 |
| ▸ | LMNA | P02545 | 6/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352046 | 1.00 | TDP1 (0.81) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL353009 | 1.00 | TDP1 (0.81) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL9814241 | 1.00 | TDP1 (0.81) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL3161153 | 0.98 | TDP1 (0.84) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| Ammonia Solution, Strong SCHEMBL7100443 | 0.96 | TDP1 (0.81) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL30294105 | 0.94 | TDP1 (0.84) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL9814242 | 0.94 | TDP1 (0.84) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL5913898 | 0.93 | TDP1 (0.70) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL30814332 | 0.93 | TDP1 (0.70) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL29162973 | 0.93 | TDP1 (0.70) | TDP1SMN1; SMN2LMNATSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | WASHINGTON UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| WO-2011098829-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | TDP1 364/4885SMN1; SMN2 4411/4885LMNA 3303/4885 |
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | NADK, NAPRT, TIPARP | TDP1 364/4885SMN1; SMN2 4411/4885LMNA 3303/4885 |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | TDP1 364/4885SMN1; SMN2 4411/4885LMNA 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.